NYSE:COR
Cencora, Inc.
A dominant healthcare distributor with massive revenue scale, strong cash flows, and a strategic platform for continued M&A growth in the US and global markets.
Key Metrics
Investment Thesis
Bull Case
COR offers compelling value for investors seeking exposure to the essential healthcare infrastructure with a track record of consistent revenue expansion through organic growth and strategic M&A. The company's massive scale provides operating leverage that can offset margin compression, while its diversified segments mitigate risks associated with specific market dynamics. Strong free cash flow generation supports ongoing shareholder returns via dividends and share repurchases, fostering capital appreciation potential.
Bear Case
Investors should be cautious regarding the secular headwinds facing the pharmaceutical distribution sector, including persistent low-margin pressures from PBMs and potential regulatory erosion of wholesale pricing power. The company's heavy reliance on acquisitions to drive growth introduces integration risks and may lead to goodwill impairment charges if synergies are not realized as expected. Additionally, the high leverage ratio relative to EBITDA could limit financial flexibility during periods of economic downturn or rising interest rates.
About Cencora, Inc.
Cencora (COR) is a leading healthcare distribution company serving hospitals, health systems, and pharmacies across North America. The company distributes prescription drugs, medical devices, and nutritional products through its diversified portfolio of acquired entities including AmerisourceBergen and McKesson. Operating in the essential healthcare supply chain, Cencora enables patient access to critical treatments while managing complex logistics for pharmaceutical manufacturers.
Analysis
Management Discussion
Cencora generated $321.33B in revenue for 2025, up from $293.96B in 2024, driven by volume growth and strategic acquisitions totaling $4.10B during the period. Despite a slight dip in net income to $1.57B compared to the prior year's $1.52B, the company maintained robust cash flow from operations of $3.88B and ended with $4.39B in cash and equivalents. The balance sheet remains conservative with long-term debt of $7.54B against significant liquidity, allowing continued investment in growth initiatives.
Industry Overview
The healthcare distribution industry is characterized by high barriers to entry due to the capital-intensive nature of logistics networks and cold chain storage requirements. Consolidation trends are reshaping the landscape as smaller players exit, leaving dominant incumbents like Cencora with significant market share advantages. Regulatory environments continue to evolve, emphasizing cost containment which pressures distributor margins but rewards those with superior operational efficiency.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $262.17B | $293.96B | $321.33B |
| Cost of Revenue | $253.21B | $284.05B | $309.85B |
| Gross Profit | $8.96B | $9.91B | $11.48B |
| Operating Expenses | $6.62B | $7.73B | $6.99B |
| Operating Income | $2.34B | $2.18B | $2.63B |
| G&A | $5.31B | $5.66B | $6.49B |
| Stock-Based Comp | $124.6M | $148.0M | $148.0M |
| D&A | $963.9M | $1.09B | $1.05B |
| Depreciation | $418.8M | $448.2M | $501.3M |
| Amortization | $553.6M | $663.5M | $556.9M |
| Other OpEx | $1.31B | $2.07B | $498.0M |
| Non-Operating Income | $-179.9M | $-171.3M | $-370.3M |
| Pre-Tax Income | $2.16B | $2.00B | $2.26B |
| Income Tax | $428.3M | $484.7M | $690.5M |
| Continuing Ops | $1.73B | $1.52B | $1.57B |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.73B | $1.52B | $1.57B |
| Minority Interest | $-12.7M | $10.2M | $13.6M |
| Net to Common | $1.75B | $1.51B | $1.55B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $42.80B | $47.72B | $52.24B |
| Cash & Equivalents | $2.59B | $3.13B | $4.36B |
| Accounts Receivable | $20.91B | $23.87B | $25.23B |
| Inventory | $17.45B | $19.00B | $20.49B |
| Prepaid Expenses | $448.9M | $450.4M | $539.3M |
| Other Current Assets | $1.39B | $1.26B | $1.63B |
| Long-Term Assets | $19.76B | $19.38B | $24.35B |
| PP&E (Net) | $2.14B | $2.18B | $2.54B |
| Intangibles | $4.43B | $4.00B | $3.77B |
| Goodwill | $9.57B | $9.32B | $13.68B |
| Operating Leases | $1.02B | $1.14B | $1.55B |
| Other LT Assets | $2.60B | $2.74B | $2.81B |
| Total Assets | $62.56B | $67.10B | $76.59B |
| Current Liabilities | $48.83B | $54.28B | $57.82B |
| Accounts Payable | $45.84B | $50.94B | $54.72B |
| Current Leases | $182.5M | $204.8M | $253.8M |
| Other Current Liab | $458.9M | $371.6M | $-136.0M |
| Long-Term Liabilities | $13.06B | $12.04B | $17.02B |
| Long-Term Debt | $4.15B | $3.81B | $7.54B |
| LT Operating Leases | $924.2M | $1.03B | $1.42B |
| Other LT Liab | $7.68B | $6.90B | $7.73B |
| Total Liabilities | $61.89B | $66.31B | $74.84B |
| Shareholders' Equity | $666.3M | $786.7M | $1.75B |
| Retained Earnings | $4.32B | $5.42B | $6.53B |
| AOCI | $-1.40B | $-989.1M | $-901.4M |
| Total L&E | $62.56B | $67.10B | $76.59B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $1.73B | $1.52B | $1.57B |
| Non-Cash Adjustments | $-8.66B | $-7.26B | $-4.38B |
| Working Capital Changes | $10.84B | $9.22B | $6.69B |
| Cash from Operations | $3.91B | $3.48B | $3.88B |
| Capital Expenditures | $458.4M | $487.2M | $668.0M |
| Cash from Investing | $-2.60B | $-618.1M | $-4.98B |
| Debt Repayments | — | — | $1.28B |
| Share Buybacks | $1.18B | $1.49B | $435.5M |
| Dividends Paid | $398.8M | $416.2M | $437.1M |
| Cash from Financing | $-2.22B | $-2.33B | $2.25B |
| FX Effect | $72.8M | $9.4M | $-50.3M |
| Net Change in Cash | $-840.6M | $545.0M | $1.10B |
| Beginning Cash | $3.59B | $2.75B | $3.30B |
| Ending Cash | $2.75B | $3.30B | $4.39B |
Frequently Asked Questions
How does Cencora, Inc. make money?
The company operates through three primary business segments: Wholesale Pharmaceutical Distribution (the core drug distribution network), Retail Services (serving retail pharmacies and specialty retailers), and Specialty Healthcare Solutions (providing services to hospitals, ambulatory surgery centers, and home health agencies).
What are the main risks for COR?
Regulatory changes such as the Inflation Reduction Act's drug importation provisions could significantly impact margins by allowing generic price competition from lower-cost foreign markets. Intense price pressure from pharmacy benefit managers (PBMs) and payers continues to erode net prices for both wholesale and retail segments. The company faces exposure to supply chain disruptions, including potential shortages of active pharmaceutical ingredients or manufacturing capacity constraints.
What is COR's competitive advantage?
Cencora possesses an entrenched multi-product, multi-channel distribution platform that offers unparalleled scale and logistics efficiency. Its diversified revenue streams across wholesale, retail, and specialty segments provide stability against cyclical shifts in any single channel. The company benefits from high switching costs for pharmaceutical manufacturers and healthcare providers due to its extensive inventory networks and established relationships.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.